Trevi Therapeutics Raises $150 Million in Stock Offering
Event summary
- Trevi Therapeutics priced its public offering of 11.6 million shares at $13.00 per share, raising approximately $150 million.
- The company has a 30-day option to issue an additional 1.74 million shares.
- The offering is expected to close on April 20, 2026.
- Proceeds will be used to fund ongoing clinical trials and general corporate purposes.
- The offering was made under a shelf registration statement filed with the SEC on November 13, 2025.
The big picture
The $150 million capital raise provides Trevi Therapeutics with a substantial runway to advance Haduvio through late-stage clinical trials and potentially towards regulatory submission. This offering underscores the continued investor interest in therapies targeting chronic cough, a significant unmet medical need with a growing patient population. However, the dilution associated with the offering will likely put pressure on the company to demonstrate rapid progress and positive clinical data.
What we're watching
- Execution Risk
- The success of Trevi's clinical trials for Haduvio remains the primary driver of its valuation, and the influx of capital will be scrutinized for efficient allocation to these efforts.
- Market Dynamics
- Given the dilution effect of the offering, investor sentiment will be sensitive to any setbacks or delays in Haduvio’s development and regulatory approval pathway.
- Regulatory Headwinds
- The FDA's eventual assessment of Haduvio’s efficacy and safety profile, particularly concerning its opioid receptor activity, will significantly impact its commercial viability and market access.
Related topics